ADBiotech Co., Ltd. (KOSDAQ:179530)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,754.00
-29.00 (-1.63%)
At close: Sep 23, 2026

ADBiotech Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-3,528-3,304-7,952-2,8632,696-2,664
Depreciation & Amortization
932.12957.021,0251,134725.66651.6
Loss (Gain) From Sale of Assets
20.41-4.43---1.82
Asset Writedown & Restructuring Costs
-1,503421.962,59045.21-
Loss (Gain) From Sale of Investments
779.38650.254,263-3,023-390.4724.16
Stock-Based Compensation
52.7881.5297.8580.28172.974.91
Provision & Write-off of Bad Debts
-759.75-163.62156.41-389.33391.19418.3
Other Operating Activities
-1,737-2,524-990.26-1,523-7,354790.4
Change in Accounts Receivable
1,9351,139-1,338660.741,197-2,135
Change in Inventory
333.47105.25-183.68450.38-1,071-232.37
Change in Accounts Payable
-378.1937.91,390-129.32-730.49631.69
Change in Unearned Revenue
----49.75--
Change in Other Net Operating Assets
1,489198.64-986.073,378-4,274257.49
Operating Cash Flow
-860.98-1,319-4,092314.93-8,592-2,186
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-15,812-15,811-193.38-239.9-726.72-3,561
Sale of Property, Plant & Equipment
21.230.3210.23--1.82
Cash Acquisitions
----1,381--
Sale (Purchase) of Intangibles
----50--
Investment in Securities
-3,233-6,2541,3224,094-1,106-1,198
Other Investing Activities
-3,282-20.33102.61-15.8634.09256.9
Investing Cash Flow
-24,690-26,0041,2412,407-2,199-4,500

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-6,0001,1001,5602,0571,000
Long-Term Debt Issued
-16,7005,500900-4,500
Total Debt Issued
26,15122,7006,6002,4602,0575,500
Long-Term Debt Repaid
--1,708-6,107-3,345-793.7-252.3
Net Debt Issued (Repaid)
9,94620,992493.24-885.191,2635,248
Issuance of Common Stock
25,4099,812--9,928198.5
Other Financing Activities
-74.83-183.44-8.83--396.88-12.77
Financing Cash Flow
35,28030,620484.41-885.1910,7945,433

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-63.98-22.65-10.24-1.56-19.039.41
Net Cash Flow
9,6653,275-2,3761,836-16.18-1,243

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-16,673-17,130-4,28575.03-9,319-5,747
Free Cash Flow Growth
------
Free Cash Flow Margin
-132.65%-132.82%-38.48%0.72%-87.66%-48.54%
Free Cash Flow Per Share
-981.76-1426.23-468.828.21-924.41-747.71
Levered Free Cash Flow
-13,637-10,704-612.42-1,259-3,247-4,961
Unlevered Free Cash Flow
-11,992-9,569-186.13-992.12-3,170-4,880

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
440.82329.13355.34333.45158.75137.52
Cash Income Tax Paid
12.26-0.18-0.925.5121.24-13.28
Change in Working Capital
3,3791,481-1,1194,310-4,879-1,479